SCHEMBL2279587

SCHEMBL2279587

CCc1ccsc1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.47
PKM P14618 1/20 0.46
MAPK8 P45983 2/20 0.41
MAPK10 P53779 1/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
MAPK1 P28482 1/20 0.41
GSK3B P49841 1/20 0.40
ALOX5 P09917 1/20 0.40
PTK2 Q05397 1/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ABCC1 P33527 1/20 0.38
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3077087 0.86 PKM (0.43) BCAT2PKMMAPK8MAPK10KMT2A
SCHEMBL4045273 0.83 PKM (0.41) BCAT2PKMMAPK8MAPK10ALDH1A1
SCHEMBL31322640 0.83 BCAT2 (0.52) BCAT2PKMMAPK8MAPK10KMT2A
SCHEMBL15286612 0.82 GPR35 (0.43) BCAT2PKMALDH1A1
SCHEMBL21554317 0.82 ALOX5 (0.39) BCAT2PKMMAPK8MAPK10KMT2A
SCHEMBL3814101 0.81 CDK8 (0.43) BCAT2PKMMAPK8MAPK10KMT2A
SCHEMBL14614093 0.81 MAPK8 (0.42) PKMMAPK8MAPK10KMT2AALDH1A1
SCHEMBL2065269 0.81 ABCC1 (0.50) KMT2AALDH1A1MEN1MAPK1GSK3B
SCHEMBL6928575 0.81 GPR35 (0.46) PKMKMT2AMEN1MAPK1
SCHEMBL21356996 0.80 BCAT2 (0.44) BCAT2PKMMAPK8MAPK10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025075821-A1 METHODS AND COMPOSITIONS FOR IMPROVING HERBICIDE DAMAGE RECOVERY IN CROPS SYNGENTA CROP PROTECTION AG (CH) 2025-04-10 WO claimed
EP-2523552-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS Merck Sharp & Dohme Corp. (US) 2012-11-21 EP claimed
WO-2011087999-A1 PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2011-07-21 WO claimed
WO-2025075821-A1 METHODS AND COMPOSITIONS FOR IMPROVING HERBICIDE DAMAGE RECOVERY IN CROPS SYNGENTA CROP PROTECTION AG (CH) 2025-04-10 WO disclosed
US-20230101819-A1 SMYD Inhibitors EPIZYME INC (US) 2023-03-30 US disclosed
US-20210198252-A1 SMYD INHIBITORS EPIZYME INC (US) 2021-07-01 US disclosed
CN-110407827-A The new crystalline form of GCC-4401C and pharmaceutical composition comprising the new crystalline form GREEN CROSS CORP 2019-11-05 CN disclosed
US-20190322660-A1 SMYD INHIBITORS Epizyme, Inc. 2019-10-24 US disclosed
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer Epizyme, Inc. (US) 2019-04-23 US disclosed
CN-106008491-B A kind of preparation method of razaxaban 苏州汇和药业有限公司 2019-04-05 CN disclosed
CN-108152412-A A kind of method with liquid chromatography for separating and determining razaxaban and its in relation to substance 乐普药业股份有限公司 2018-06-12 CN disclosed
US-20170355695-A1 SMYD Inhibitors Epizyme, Inc. (US) 2017-12-14 US disclosed
CN-104478866-B Oxazolidinone compounds and its application in medicine 广东东阳光药业有限公司 2017-07-07 CN disclosed
CN-105593232-A Benzoxazoloxazinone compounds as coagulation factor Xa inhibitors NORTH CHINA PHARMACEUTICAL NEW DRUG R & D CO LTD 2016-05-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer SMYD3, SMYD2, SNRPD3 BCAT2 1595/4885PKM 3509/4885MAPK8 3598/4885
US-20170355695-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 BCAT2 544/4885PKM 3668/4885MAPK8 3861/4885
US-20210198252-A1 SMYD INHIBITORS SMYD3, SMYD2, SMURF2 BCAT2 565/4885PKM 3671/4885MAPK8 3851/4885
US-20190322660-A1 SMYD INHIBITORS SMYD2, SMYD3, SMURF2 BCAT2 649/4885PKM 3834/4885MAPK8 3713/4885
US-20230101819-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 BCAT2 538/4885PKM 3671/4885MAPK8 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.